Advertisement
KRRO vs MGNX
Which Stock Would AI Choose? Korro Bio (KRRO) vs. MacroGenics (MGNX) Stock Comparison
Key Takeaways
- Korro Bio (KRRO) is a clinical-stage genetic medicines company focused on RNA editing, while MacroGenics (MGNX) develops antibody-based cancer therapeutics — two distinct biotech business models with different catalysts and risk profiles.
- KRRO recently pivoted to a new lead asset, KRRO-121, after its prior AATD program failed in late 2025, while MGNX is executing a business transformation centered on divesting its manufacturing operations to fund its antibody-drug conjugate (ADC) pipeline.
- MGNX has generated substantially more revenue and holds a larger cash position, whereas KRRO relies primarily on collaboration income and a leaner balance sheet.
- Analyst sentiment skews favorable for both names, with KRRO carrying a "Strong Buy" consensus and MGNX an "Outperform" consensus, though both stocks remain highly volatile and speculative.
- For more information on each company's headlines and daily price action, explore the KRRO Major News and KRRO Today's Price Move pages, as well as the MGNX Major News and MGNX Today's Price Move pages.
- To see how AI evaluates opportunities like these in real time, explore the Trending AI Robots section.
Introduction
Investors comparing KRRO and MGNX are effectively weighing two different approaches to drug development within the volatile clinical-stage biotechnology sector. Korro Bio is pioneering RNA editing to create genetic medicines, while MacroGenics engineers antibody-based therapies for cancer. Both trade at small-cap levels, carry no meaningful product revenue, and are driven primarily by clinical data readouts, regulatory milestones, and financing decisions. This stock comparison is most relevant to growth-oriented and event-driven traders comfortable with elevated risk, as well as investors seeking exposure to differentiated biotech platforms. Understanding each company's pipeline, balance sheet, and recent momentum helps clarify how their market positioning and relative performance have diverged in recent months.
KRRO Overview and Recent Performance
KRRO, or Korro Bio, is a clinical-stage biopharmaceutical company developing genetic medicines based on RNA (ribonucleic acid) editing, a technique that makes precise, transient single-base edits to RNA rather than DNA. The company suffered a notable setback when its prior lead program, KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), reported negative results, prompting an amendment to its Novo Nordisk research agreement. Since then, management has shifted focus to a new lead asset, KRRO-121, an RNA-editing therapy for hyperammonemia (elevated blood ammonia) in urea cycle disorders and hepatic encephalopathy. Recent weeks have brought a series of analyst upgrades — including Raymond James, William Blair, and a Buy initiation from Citigroup — alongside insider buying by major shareholder Lynx1 Capital. The company has dosed its first cohort in the Phase 1/2 ANCHOR trial for KRRO-121, and shares have rallied sharply off depressed levels, though they remain well below their 52-week highs.
MGNX Overview and Recent Performance
MGNX, or MacroGenics, is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including ADCs (antibody-drug conjugates) and bispecific DART and TRIDENT molecules. The company is advancing a focused pipeline led by MGC026, a B7-H3-targeting ADC, and MGC028, an ADAM9-targeting ADC, with initial data disclosures expected across 2026. In a significant recent development, MacroGenics agreed to sell its GMP (Good Manufacturing Practice) drug-substance manufacturing operations to Bora Pharmaceuticals for $122.5 million upfront, while separately monetizing additional ZYNYZ royalty interests for $60 million. These moves are intended to sharpen focus on drug discovery and extend the cash runway through 2028. The stock has delivered substantial gains over the past year, supported by partnership milestones from Incyte, Sanofi, and Gilead, though it remains below consensus price targets.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's best-performing AI trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, yet only the most suitable for current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance, and the sets of tickers they monitor, allowing traders to match automated strategies to their own objectives. Many of the featured robots display detailed performance statistics, trade histories, and success rates, giving users data-driven insight into how each bot behaves across shifting market regimes. For traders interested in how machine learning interprets setups like the KRRO and MGNX comparison, reviewing the Trending AI Robots page is a practical starting point.
Head-to-Head Comparison
Despite both being clinical-stage biotechs, KRRO and MGNX differ sharply across several dimensions. In terms of business model, KRRO is a pure platform play with minimal revenue tied to its Novo Nordisk collaboration, while MGNX generates tangible revenue from contract manufacturing, royalties, and partnered milestones — though its manufacturing income is set to decline following the Bora divestiture. On growth drivers, KRRO's thesis hinges almost entirely on KRRO-121 and future RNA-editing candidates, whereas MGNX spreads its catalysts across multiple ADC programs and partnership milestones. From a financial standpoint, MGNX holds a larger cash balance and has extended its runway through 2028; KRRO's cash position is smaller but management also projects runway into the second half of 2028. Risk profiles differ as well: KRRO is recovering from a failed lead program, while MGNX is repositioning after pausing parts of its LINNET study and exiting a gynecologic cancer cohort. Recent momentum has favored both names, with MGNX posting one of the strongest year-to-date gains in its history and KRRO rebounding after prolonged weakness.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely view MGNX as the more stable of the two names, given its multiple revenue streams, larger cash position, diversified pipeline, and clearer near-term catalysts in the form of ADC data readouts and non-dilutive capital. At the same time, KRRO may present a more pronounced momentum-driven opportunity following its pipeline pivot and the recent wave of analyst upgrades and insider buying. The AI's relative preference would ultimately depend on whether it prioritizes trend consistency and balance-sheet stability — which favor MGNX — or near-term catalyst intensity and sentiment recovery, which currently favor KRRO. Neither profile suggests a low-risk setup, and both remain subject to binary clinical outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRRO is a StrongBuy and MGNX is a Hold.
Momentum Indicator for KRRO turns positive, indicating new upward trend
KRRO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 73 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for KRRO just turned positive on October 20, 2026. Looking at past instances where KRRO's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 46 cases where KRRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KRRO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KRRO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.498). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MGNX's Indicator enters downward trend
The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator formed such a pattern. In 201 of the 222 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MGNX turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MGNX's RSI Indicator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MGNX as a result. In 78 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +5.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.498). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KRRO | MGNX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 64 Fair valued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 38 | 64 | |
P/E GROWTH RATING 1..100 | 79 | 11 | |
SEASONALITY SCORE 1..100 | 3 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KRRO's Valuation (64) in the null industry is in the same range as MGNX (88) in the Biotechnology industry. This means that KRRO’s stock grew similarly to MGNX’s over the last 12 months.
KRRO's Profit vs Risk Rating (100) in the null industry is in the same range as MGNX (100) in the Biotechnology industry. This means that KRRO’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's SMR Rating (97) in the Biotechnology industry is in the same range as KRRO (100) in the null industry. This means that MGNX’s stock grew similarly to KRRO’s over the last 12 months.
KRRO's Price Growth Rating (38) in the null industry is in the same range as MGNX (64) in the Biotechnology industry. This means that KRRO’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for KRRO (79) in the null industry. This means that MGNX’s stock grew significantly faster than KRRO’s over the last 12 months.
| KRRO | MGNX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 67% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| Advances ODDS (%) | 1 day ago 86% | 1 day ago 84% |
| Declines ODDS (%) | 28 days ago 90% | 5 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KRRO’s FA Score shows that 0 FA rating(s) are green while MGNX’s FA Score has 1 green FA rating(s).
- KRRO’s FA Score: 0 green, 5 red.
- MGNX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KRRO’s TA Score shows that 5 TA indicator(s) are bullish while MGNX’s TA Score has 5 bullish TA indicator(s).
- KRRO’s TA Score: 5 bullish, 6 bearish.
- MGNX’s TA Score: 5 bullish, 3 bearish.
Price Growth
KRRO (@Biotechnology) experienced а -5.59% price change this week, while MGNX (@Biotechnology) price change was +0.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.
Reported Earning Dates
KRRO is expected to report earnings on Mar 30, 2027.
MGNX is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+2.23% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KRRO and
Correlation & Price change
A.I.dvisor indicates that over the last year, KRRO has been loosely correlated with MGNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if KRRO jumps, then MGNX could also see price increases.
| Ticker / NAME | Correlation To KRRO | 1D Price Change % | ||
|---|---|---|---|---|
| KRRO | 100% | +1.42% | ||
| MGNX - KRRO | 45% Loosely correlated | +0.43% | ||
| TRDA - KRRO | 43% Loosely correlated | -4.09% | ||
| RLAY - KRRO | 42% Loosely correlated | +9.62% | ||
| NRIX - KRRO | 37% Loosely correlated | +5.49% | ||
| AVIR - KRRO | 37% Loosely correlated | +2.32% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| WDNA | 23.91 | 0.82 | +3.57% |
| WisdomTree BioRevolution Fund (WDNA) | |||
| KCE | 160.98 | 4.60 | +2.94% |
| State Street SPDR S&P Capital Markets ETF (KCE) | |||
| FLIN | 36.70 | 0.39 | +1.07% |
| Franklin FTSE India ETF (FLIN) | |||
| RMMZ | 13.95 | -0.01 | -0.07% |
| RiverNorth Managed Duration Municipal Income Fund II | |||
| UXRP | 8.70 | -1.34 | -13.35% |
| ProShares Ultra XRP ETF (UXRP) | |||